Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/28/2025 | $4.00 | Buy | Rodman & Renshaw |
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif., Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the develo
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (NASDAQ:TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing. Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad™ and for pre-launch preparations. Talphera is a specialty pharm
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial. The enrollment of 17 patients is a milestone that was required to be achieved, and announced, as one of the conditions to close the se
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
PRE 14A - TALPHERA, INC. (0001427925) (Filer)
10-Q - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical
SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial res
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)